Канада - англійська - Health Canada

teva canada limited - atazanavir (atazanavir sulfate) - capsule - 150mg - atazanavir (atazanavir sulfate) 150mg - hiv protease inhibitors

Канада - англійська - Health Canada

teva canada limited - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors

Канада - англійська - Health Canada

teva canada limited - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: magnesium stearate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; lactose monohydrate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; purified water; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: sodium starch glycollate type a; purified water; lactose monohydrate; magnesium stearate; hydrophobic colloidal silica anhydrous; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - atazanavir 300 mg - evotaz® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults. limitations of use: evotaz is contraindicated: table 1 displays drugs that are contraindicated with evotaz. alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antianginal ranolazine potential for serious and/or life-threatening reactions. antiarrhythmics dronedarone potential for increased dronedarone concentrations. anticonvulsants carbamazepine, phenobarbital, phenytoin potential for decreased atazanavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. antigout colchicine contraindicated in patients with renal and/or hepatic impairment due to the potential for serious and/or life-threatening reactions. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeut

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: purified water; lactose monohydrate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies